Merck probe over Remicade closed, but CMA warns over drug discounting
MLex Summary: An antitrust probe into a suspected anticompetitive discount scheme by drugmaker Merck Sharp & Dohme has been closed by the Competition and Markets Authority after it found no grounds...To view the full article, register now.
Already a subscriber? Click here to view full article